Nutriband Co-Founder Gareth Sheridan Returns as CEO
Nutriband (NASDAQ: NTRB / NTRBW) announced that co-founder Gareth Sheridan has returned as CEO effective October 27, 2025. From August 10 to October 27, co-founder and chairman Serguei Melnik covered CEO duties.
Mr. Sheridan will lead the company through the remainder of 2025 toward a targeted NDA filing in 2026 for AVERSA FENTANYL, an abuse‑deterrent transdermal fentanyl patch. Management cites a Health Advances market analysis estimating peak U.S. sales of $80M–$200M. The AVERSA technology is protected by patents in 46 countries.
Nutriband (NASDAQ: NTRB / NTRBW) ha annunciato che il cofondatore Gareth Sheridan è tornato CEO con effetto dal 27 ottobre 2025. Dal 10 agosto al 27 ottobre, il cofondatore e presidente Serguei Melnik ha coperto i compiti di CEO.
Il signor Sheridan guiderà l'azienda nel resto del 2025 verso una prevista presentazione dell'NDA nel 2026 per AVERSA FENTANYL, un cerotto transdermale di fentanyl anti‑abuso. La direzione cita un'analisi di mercato Health Advances che stima vendite massime negli Stati Uniti di 80–200 milioni di dollari. La tecnologia AVERSA è protetta da brevetti in 46 paesi.
Nutriband (NASDAQ: NTRB / NTRBW) anunció que el cofundador Gareth Sheridan ha regresado como CEO con efecto a partir del 27 de octubre de 2025. Desde el 10 de agosto hasta el 27 de octubre, el cofundador y presidente Serguei Melnik llevó las funciones de CEO.
El señor Sheridan dirigirá la empresa hasta el resto de 2025 hacia una presentación de NDA en 2026 para AVERSA FENTANYL, un parche transdérmico de fentanilo para evitar abusos. La dirección cita un análisis de mercado de Health Advances que estima ventas máximas en EE. UU. de $80M–$200M. La tecnología AVERSA está protegida por patentes en 46 países.
Nutriband (NASDAQ: NTRB / NTRBW)은 공동 설립자 Gareth Sheridan가 2025년 10월 27일부로 CEO로 복귀했다고 발표했습니다. 8월 10일부터 10월 27일까지 공동 설립자이자 의장인 Serguei Melnik가 CEO 직무를 대행했습니다.
Sheridan 씨는 2025년 남은 기간 동안 AVERSA FENTANYL에 대한 2026년 NDA 제출를 목표로 회사를 이끌 것이며, 남용 억제를 위한 트랜스더멀 펜타닐 패치를 위해서입니다. 경영진은 Health Advances의 시장 분석을 인용하며 미국 매출의 정점을 미화 8000만 달러에서 2억 달러로 추정합니다. AVERSA 기술은 46개국에서 특허로 보호됩니다.
Nutriband (NASDAQ: NTRB / NTRBW) a annoncé que le cofondateur Gareth Sheridan est revenu en tant que PDG à compter du 27 octobre 2025. Du 10 août au 27 octobre, le cofondateur et président Serguei Melnik a assuré les fonctions de PDG.
M. Sheridan dirigera l'entreprise pour le reste de 2025 en vue d'un dépôt NDA en 2026 pour AVERSA FENTANYL, un patch transdermique fentanil anti‑abus. La direction cite une analyse de marché Health Advances estimant des ventes maximales aux États‑Unis de 80 M$ à 200 M$. La technologie AVERSA est protégée par des brevets dans 46 pays.
Nutriband (NASDAQ: NTRB / NTRBW) gab bekannt, dass Mitbegründer Gareth Sheridan als CEO ab dem 27. Oktober 2025 zurückkehrt. Vom 10. August bis zum 27. Oktober übernahm Mitbegründer und Vorsitzender Serguei Melnik die CEO-Aufgaben.
Herr Sheridan wird das Unternehmen im verbleibenden Jahr 2025 auf eine NDA‑Einreichung im Jahr 2026 für AVERSA FENTANYL vorbereiten, einen missbrauchsverhindernden transdermalen Fentanyl‑Pflaster. Die Geschäftsführung verweist auf eine Health Advances‑Marktanalyse, die US‑Verkaufshöhe von 80 Mio. bis 200 Mio. USD schätzt. Die AVERSA‑Technologie ist durch Patente in 46 Ländern geschützt.
Nutriband (NASDAQ: NTRB / NTRBW) أعلن المؤسس المشارك Gareth Sheridan أنه عاد كرئيس تنفيذي اعتباراً من 27 أكتوبر 2025. من 10 أغسطس حتى 27 أكتوبر تولّى المؤسس المشارك ورئيس مجلس الإدارة Serguei Melnik مهام الرئيس التنفيذي.
سيقود السيد شيريدان الشركة لبقية عام 2025 نحو تقديم NDA في 2026 لـ AVERSA FENTANYL، لوحشية فنتانيل عبر لصقة تراندرمال ممانعة للإساءة. تعتمد الإدارة على تحليل سوق Health Advances الذي يقدر المبيعات القصوى في الولايات المتحدة من 80 مليون إلى 200 مليون دولار. تقنية AVERSA محمية ببراءات في 46 دولة.
Nutriband (NASDAQ: NTRB / NTRBW) 公告称联合创始人 Gareth Sheridan 已于 2025 年 10 月 27 日起恢复担任 CEO。自 8 月 10 日至 10 月 27 日，联合创始人兼董事长 Serguei Melnik 代理 CEO 职务。
Sheridan 先生将带领公司完成 2025 年剩余时间，目标是在 2026 年就 AVERSA FENTANYL 提交 NDA，该产品为防滥用的经皮给药芬太尼贴片。管理层引用 Health Advances 的市场分析，估计美国销售高峰为 $80M–$200M。AVERSA 技术在 46 个国家受到专利保护。
- Founder Gareth Sheridan reinstated as CEO effective Oct 27, 2025
- Company targets NDA filing in 2026 for AVERSA FENTANYL
- Peak U.S. sales estimate of $80M–$200M (Health Advances)
- AVERSA patents issued in 46 countries
- Interim CEO period (Aug 10–Oct 27, 2025) may indicate recent leadership disruption
- NDA filing is a targeted 2026 event, not a completed regulatory milestone
ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO.
During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken over the responsibilities of CEO. Mr Sheridan has returned to the position of CEO effective immediately and will guide the company through the final 2025 framework towards the target NDA filing in 2026 for AVERSA Fentanyl.
AVERSA FENTANYL has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA FENTANYL has the potential to reach peak annual US sales of
The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
Who is the new CEO of Nutriband (NTRB) as of October 27, 2025?
Why did Serguei Melnik serve as CEO for Nutriband (NTRB) in 2025?
When is Nutriband targeting an NDA filing for AVERSA FENTANYL (NTRB)?
What are the projected peak U.S. sales for AVERSA FENTANYL cited by Nutriband?
How broad is Nutriband's intellectual property coverage for AVERSA technology?
